| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,003 |
8,294 |
$736K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,441 |
5,034 |
$309K |
| 36415 |
Collection of venous blood by venipuncture |
8,118 |
7,552 |
$38K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
383 |
379 |
$28K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
304 |
295 |
$25K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
226 |
194 |
$19K |
| 80061 |
Lipid panel |
1,173 |
1,151 |
$15K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
790 |
770 |
$11K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
200 |
161 |
$10K |
| 80053 |
Comprehensive metabolic panel |
851 |
834 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
158 |
156 |
$8K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
75 |
67 |
$6K |
| 84443 |
Thyroid stimulating hormone (TSH) |
390 |
380 |
$6K |
| 90686 |
|
581 |
571 |
$6K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
69 |
63 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
491 |
486 |
$5K |
| 80050 |
General health panel |
94 |
91 |
$5K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
604 |
569 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
129 |
116 |
$4K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
141 |
139 |
$4K |
| 92567 |
|
357 |
335 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
149 |
146 |
$4K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
837 |
822 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
147 |
132 |
$3K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
28 |
28 |
$3K |
| 92551 |
|
377 |
367 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
92 |
91 |
$3K |
| 0054A |
|
55 |
55 |
$2K |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
72 |
66 |
$2K |
| 85027 |
|
244 |
241 |
$2K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
42 |
37 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
42 |
42 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
42 |
42 |
$1K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
15 |
14 |
$1K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
14 |
13 |
$1K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
33 |
27 |
$945.39 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
15 |
15 |
$914.23 |
| 99490 |
Ccm add 20min |
119 |
119 |
$872.19 |
| 0004A |
|
34 |
34 |
$818.99 |
| 0124A |
|
29 |
26 |
$742.28 |
| 90651 |
|
15 |
12 |
$621.67 |
| 90715 |
|
26 |
25 |
$619.74 |
| 92557 |
|
30 |
26 |
$578.41 |
| 99173 |
|
373 |
363 |
$575.97 |
| 90656 |
|
33 |
33 |
$570.60 |
| 87481 |
|
15 |
15 |
$498.92 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
15 |
15 |
$498.92 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
15 |
14 |
$486.18 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
54 |
51 |
$423.69 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
29 |
28 |
$357.91 |
| 81001 |
|
78 |
74 |
$247.19 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
14 |
12 |
$236.56 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
28 |
28 |
$218.20 |
| 86803 |
|
17 |
17 |
$217.71 |
| G0008 |
Administration of influenza virus vaccine |
19 |
15 |
$178.60 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
17 |
14 |
$148.35 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
80 |
72 |
$129.50 |
| 83735 |
|
15 |
15 |
$109.84 |
| 85018 |
|
40 |
39 |
$88.21 |
| 82043 |
|
14 |
13 |
$82.99 |
| 96127 |
|
18 |
17 |
$70.60 |
| 99188 |
|
12 |
12 |
$65.76 |
| 81003 |
|
25 |
25 |
$52.34 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
583 |
494 |
$0.00 |